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Abstract. Objectives: To analyze the prognostic value of microsatellite instability (MSI) in a population-based study of FIGO
stage 1–4 endometrial endometrioid adenocarcinomas.
Study design: Survival analysis in 273 patients of MSI status and clinico-pathologic features. Using a highly sensitive penta-
plex polymerase chain reaction to establish MSI status, cases were divided into microsatellite stable (MSS), MSI-low (MSI-L,
1 marker positive) and MSI-high (MSI-H, 2–5 markers positive).
Results: After 61 months median follow-up (1-209), 34 (12.5%) of the patients developed metastases but only 6.4% of the
FIGO 1. MSI (especially as MSI-H vs. MSS/MSI-Lcombined) was prognostic in FIGO 1 but not in FIGO 2–4. The 5 and 10 year
recurrence-free survival rates were 98% and 95% in the MSS/MSI-L vs. 85% and 73% in the MSI-H patients (p = 0.005).
Conclusions: MSI-H status assessed by pentaplex polymerase chain reaction is an indicator of poor prognosis in FIGO 1, but
not in FIGO 2–4 endometrial endometrioid adenocarcinomas.
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1. Introduction
Endometrial adenocarcinoma is the most frequent
gynecologic cancer. The disease-related death rate in
FIGO stage 2–4 range from 20–80% and greater while
in the “favorable” early stage FIGO 1, the death rate
is only 5 to 10% [3,31]. The latter has been stable for
decades [41]. This wide range of disease-related death
*Corresponding author: Jan P. Baak, Department of Pathology,
Stavanger University Hospital, Armauer Hansensvei 20, 4068, Sta-
vanger, Norway. Tel.: +47 5151 9378; Fax: +47 5151 9910; E-mail:
jpabaak@yahoo.com.
rate prompts the search for more reliable prognostic in-
dicators both to enable more accurate triaging of pa-
tients concerning treatment modalities, and to gain bet-
ter mechanistic insights into the disease.
In early FIGO stage 1 cancers, histologic type, grade
and myometrium invasion depth (MI) are often used
to determine individual therapy, but their prognos-
tic accuracy and reproducibility are not always opti-
mal [3,41,43]. Increased understanding of the molecu-
lar biology in endometrial carcinogenesis has revealed
several promising prognostic and predictive biomark-
ers, such as microsatellite instability (MSI), a char-
acteristic finding in cancers deficient in DNA mis-
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match repair (MMR), seen in 9–45% of sporadic en-
dometrial cancers (Table 1) [1,4–7,10,12,16,17,19,25,
26,28,29,32,33,42,44]. In contrast to Hereditary Non-
Polyposis Colorectal Cancer (HNPCC) or Lynch syn-
drome, which is an autosomal dominant condition in-
volving germline MMR gene mutation, sporadic en-
Table 1
Studies cited in PubMed on MSI in endometrial cancer
Author No. Nos type I/ FIGO FIGO 1 MSI MSI-High(+) % MSI impact
cases type 2 stages endometrioid markers on prognosis
separately
analysed?
Peiro et al. [32] 89 76/13 All No information D2S123 11 Not prognostic
D5S346
Mfd15
BAT25
BAT26
Fiumicino et al. [12] 65 ? 1 and 2 No information D2S123 17 Unfavorable
D2S119 p = 0.0004
D9S171
D9S157
D10S216
BAT26
Wong et al. [42] 80 80/0 No information Yes D2S123D5 NR21 26 No information
S346D17S NR24
250 NR27
BAT25 BAT25
BAT26 BAT26
Black et al. [7] 473 379/94 Mix No information D2S123 20 Favorable
D5S346 p = 0.005
D17S250
BAT25
BAT26
An et al. [1] 93 93/0 Only 63 staged No information D2S123 20 No information
D5S346
D17S250
BAT25
BAT26
MacDonald 259 234/25 All No information D10S187 45 Not prognostic
et al. [25] D18S55
D18S58
BAT26
BAT40
Zighelboim et al. [44] 446 446/0 1–4 308 stage 1 D2S123 33 Not prognostic
(not analysed D5S346
separately) D17S250
BAT25
BAT26
Muresua et al. [28] 86 ? 1–3 No information D2S123 32 Not prognostic
D5S346
D17S250
BAT25
BAT26
A. Steinbakk et al. / MSI in endometrial endometrioid adenocarcinoma 247
Table 1
(Continued)
Author No. Nos type I/ FIGO FIGO 1 MSI MSI-High(+) % MSI impact
cases type 2 stages endometrioid markers on prognosis
separately
analysed?
Honore et al. [17] 218 218/0 No information No information BAT26 16 No information
Hirasawa et al. [16] 43 ? 1–4 30 stage 1 and 2 D2S123 28 No information
D5S346
D17S250
BAT26
BAT25
MSH3
MSH6
TGF RII
BAX
MBD4A10
MBD4A6
Ju et al. [19] 50 50/0 1–4 30 stage 1 D5S346 24 No information
(not analysed D17S250
separately) D2S123
BAT25
BAT26
Maxwell et al. [26] 131 131/0 All 81 stage 1, 2 and 3a D14S65 22 Favorable
analysed in one group D14S297 p = 0.03
BAT26
Ørbo et al. [29] 105 Mix All No information D2S123 20 Not prognostic
D5S346
BAT25
BAT26
TGF RII
p53-1
Baldinu et al. [4] 116 97/19 I to 3 No D2S123 34 Not prognostic
D5S346
D17S250
BAT25
BAT26
Caduff et al. [10] 109 86/23 All No D2S123 9 Unfavorable
D5S107 p = 0.0005
HUMCA1126
D10S197
D11S904
D13S175
D17S13223
D18S34
Pijnenborg et al. [33] 88 88/0 I Yes BAT25 14–16 Not prognostic
BAT26
Basil et al. [5] 229 173/56 All No D2S123 31 Not prognostic
D5S346
D17S250
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Table 1
(Continued)
Author No. Nos type I/ FIGO FIGO 1 MSI MSI-High(+) % MSI impact
cases type 2 stages endometrioid markers on prognosis
separately
analysed?
BAT25
BAT26
Bilbao et al. [6] 93 93/0 All Stage 1 and 2 NR21 22 Unfavorable
separately analysed NR24 p = 0.048
NR27
BAT25
BAT26
Current study 224 224/0 I Yes NR21 16 Unfavorable, but
only as
MSS + MSI-low
versus MSI-high,
p = 0.005
NR24
NR27
BAT25
BAT26
dometrial cancers arise from epigenetic changes in-
volving primarily hMLH1 promoter methylation re-
sulting in gene inactivation. There are two pathways
of genomic instability, chromosomal instability (CI)
and microsatellite instability (MSI). CI is characterized
by frequent loss of heterozygosity (LOH) with aneu-
ploidy, is associated with p53 mutation and is typical of
non-endometrioid (type II) endometrial cancers. The
other MSI pathway involves defective MMR resulting
in abnormalities at the nucleotide level, preserved near-
diploidy, is often associated with PTEN and K-ras mu-
tations, and typically occurs in endometrioid (type I)
endometrial cancers.
In many MSI studies, a mix of early and late FIGO
stage cancers of all histologic types has been analyzed;
therefore the results of these studies can not be directly
extrapolated to early stage cancers of the endometri-
oid type (which are by far the most common) as the
type II endometrial cancers follow a different mole-
cular development pathway [15]. Mixing types I and
II endometrial cancers in fact may seriously blur the
analysis. Not surprisingly, the results of different stud-
ies published thus far on MSI vary greatly. A large mul-
ticenter study consisting of 446 endometrioid (type I)
endometrial cancers only and found that MSI has no
prognostic value [44]. However, in spite of the large
numbers of patients, it also mixed all stages which may
have seriously biased the conclusions for FIGO stage 1
type I cancers. Another shortcoming was that the MSI
markers used were less sensitive than the recently de-
scribed ones assessed by the pentaplex polymerase
chain reaction assay [8,9,42]. Another recent study of
interest investigated early stage radiation-treated en-
dometrioid tumors only with the same MSI markers as
ours, and concluded on a negative prognostic value for
MSI-H patients [6].
In the present study we investigated whether MSI
assessed with the pentaplex polymerase chain reaction
assay containing five sensitive mononucleotide repeats
has prognostic value in a population-based study of
consecutive endometrioid endometrial cancer patients.
2. Materials and methods
The current MSI study is part of a project on en-
dometrial carcinogenesis, approved prior to the initi-
ation of the study by the Regional Ethics Committee
and Norwegian Data Inspection.
2.1. Cases
The cohort used in this study was population-based
from Rogaland-south, a county in South West Norway
covering approximately 350,000 inhabitants. From
January 1, 1989 through December 31, 2004, 363 cases
of endometrial cancer were diagnosed at the Stavanger
University Hospital, the only hospital in the region.
From this group the following cases were excluded:
lack of follow-up (7 cases), no adequate histologic
material available for additional studies (39 cases) or
no diagnostic evidence of invasive adenocarcinoma
on histologic material reviewed by two gynecologic
pathologists (EG, JB) (13 cases), leaving 304 patients
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in the study. In agreement with other large studies,
none of the patients in our series received preoperative
hormonal or chemotherapy. Surgery was performed
shortly after the pathology diagnosis was rendered. Pa-
tients with FIGO stage 1A, 1B or 1C, well and mod-
erately differentiated cancers, received only surgical
treatment consisting of total abdominal hysterectomy
with bilateral salpingo-oophorectomy. Adjuvant post-
operative radiotherapy (RT) was administered to all pa-
tients with FIGO stage 1C poorly differentiated can-
cers, and all patients with FIGO stage 2 cancers. Pa-
tients with FIGO stages 3 and 4 cancers were treated
post-operatively with radiation or chemotherapy or
both. All patients were followed at 3-monthly inter-
vals. Standard surveillance included physical exami-
nation and cytologic smears for at least 2 years af-
ter initial treatment. Assessments with additional cy-
tologic and imaging studies or directed biopsies were
performed as clinically indicated at the discretion of
the treating physician. Recurrent disease was histolog-
ically confirmed.
The sampling and tissue processing procedures were
standardized as follows. Tissue slices of approxi-
mately 4 mm in thickness were routinely fixed in
4% buffered formaldehyde, dehydrated, paraffin em-
bedded, sections cut at 4-µm and haematoxylin-eosin-
saffran (HES) stained. Histologic grade and type, cer-
vical involvement and myometrium invasion of all
cases were re-reviewed by two of us (EG, JB) and
histologic grade and type of the FIGO 1 cases was
re-reviewed by one more independent gynecologic
pathologist (AM, EG, JB) using the WHO 2003 cri-
teria. Staging was performed according to the origi-
nal FIGO staging system [23]. In the few cases where
there was disagreement between the reviewing pathol-
ogists whether a case was type 1, type 2, neuroen-
docrine cancer or sarcoma, additional immunohisto-
chemical studies including p16, p53, chromogranin,
synaptophysin, pan-CK, ER, E-cadherin and desmin
were performed to clarify the diagnosis. After the re-
review the 304 cases were distributed as follows: FIGO
stage 1, 248 cases (82%); FIGO stage 2, 28 cases
(9%); FIGO stage 3, 18 cases (6%) and FIGO stage
4, 10 cases (3%) (similar distribution to the one seen
in other studies). There were 30 non-endometrioid en-
dometrial cancers. One more case was excluded be-
cause the sections and blocks were not available at the
time of review by one of us (AM), leaving 273 en-
dometrioid endometrial cancers and 224 FIGO 1 can-
cers for analysis. 62 cases were excluded from MSI
analysis (too little material/bad quality material, can-
cer tissue cut through, n = 45 + 17) leaving 211 cases
for MSI analysis.
2.2. Microsatellite analysis
Microsatellite analysis was performed on DNA iso-
lated from archived, paraffin-embedded tissue blocks
using tissue from the invasive front of each tumor
(avoiding areas with extensive necrosis or normal tis-
sue), using the QIAamp DNA Mini Kit (Qiagen™,
Hilden, Germany) following the manufacturer’s pro-
tocol for DNA-isolation. MSI analysis was performed
using five microsatellite markers (BAT26, BAT25,
NR21, NR24, NR27) known to be quasimonomorphic,
with low risk for polymorphisms in the Caucasian pop-
ulation, as previously described [8,9,37,40]. The dif-
ference in MSI markers used by us, and in the large
endometrioid endometrial cancer study by Zighelboim
et al. [44] was considerable: only BAT25 and BAT26
were the same. Markers NR21, NR24 and NR27 are
sensitive for MSI detection as described elsewhere [8,
9,40]. The selected markers showed a high sensitivity
for MSI detection without the need for matching with
patient’s normal DNA. The primer sequences are listed
in Table 2 and primers were labelled with either FAM
or HEX fluorescent dyes. PCR-amplification was per-
formed under standard conditions. The reactions were
incubated at 95◦C for five minutes followed by 35 cy-
cles of 95◦C, 56◦C and 72◦C for one minute each. The
product length was analysed using a sequencer (Ge-
neAnalyzer™ 3130XL, Applied Biosystems) with the
GeneMap™ software. MSI in any marker was visual-
ized as changes in the product length (Fig. 1). Insta-
bility in 40% (2 of 5) of the markers was classi-
fied as high-frequency microsatellite instability (MSI-
H), in 1 of 5 markers as low-frequency (MSI-L), and in
no markers as microsatellite stable (MSS). In line with
other studies, MSI-L were grouped together with MSS
cases for most analyses.
2.3. Statistical analysis
The quality of the database input data was controlled
by checking descriptive statistics and cross tables for
all patients, to trace unlikely values or combinations.
We analyzed the following endpoints: alive with lo-
cal or distant recurrence (n = 6), and dead of en-
dometrial cancer (n = 28). As recurrence and dead
of endometrial cancer gave the same results, the re-
currence cases and dead of endometrial cancer cases
were grouped together and further described. Patients
with death from other non-endometrial cancer related
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Table 2
Primers used for microsatellite analysis
Marker Gene Primer sequence Gene bank number Average PCR product size (bp)
BAT26 hMSH2 F: 5′- TGA CTA CTT TTG ACT TCA GCC -′3 U41210 120
R: 5′- AAC CAT TCA ACA TTT TTA ACC C -′3
BAT25 c-kit F: 5′- TCG CCT CCA AGA ATG TAA GT -′3 L04143 124
R: 5′- TCT GCA TTT TAA CTA TGG CTC -′3
NR21 SLC7A8 F: 5′- GAG TCG CTG GCA CAG TTC TA -′3 NM_012244 109
R: 5′- CTG GTC ACT CGC GTT TAC AA -′3
NR24 Zink-finger 2 F: 5′- GCT GAA TTT TAC CTC CTG AC -′3 X60152 131
(ZNF-2) R: 5′- ATT GTG CCA TTG CAT TCC AA -′3
NR27 Inhibitor of apoptosis F: 5′- AAC CAT GCT TGC AAA CCA CT -′3 AF070674 87
Protein-1 (MIHC) R: 5′- CGA TAA TAC TAG CAA TGA CC -′3
Notes: F denotes forward primer sequence; R denotes reverse primer sequence. The fluorescent markers used were FAM for BAT26, NR24 and
NR27, and HEX for BAT25 and NR21.
Fig. 1. MSI analysis electropherogram of the 5 markers used. Typical allelic profiles for the different markers. Top line shows microsatellite
stable (MSS) tumors; bottom line shows tumors with microsatellite instability (MSI) displaying changes in product size (two peaks) with a shift,
typically of about 10 bp length (bp denotes base pairs).
causes, or patients lost to follow-up were censored at
the last known follow-up date as alive, no evidence of
disease (ANED). Analyses were performed by SPSS
version 15 (SPSS, Chicago, IL, USA). For age (a con-
tinuous variable) we used the median, tertiles and quar-
tiles as thresholds, or the threshold with the objectively
best sensitivity and specificity assessed by Receiver
Operating Curve (ROC) analysis (MedCalc Software,
Mariakerke, Belgium), for details of the ROC tech-
nique [22]. The two methods always pointed to the
same threshold which was used in further analyzes.
The chi-square test was used to determine the relation-
ship between MSI-status and the clinico-pathological
risk factors. Univariate analysis was performed using
the Kaplan–Meier method, and differences in survival
were estimated by the Breslow and log-rank tests. Haz-
ard ratios (HR) and 95% confidence intervals (95% CI)
were calculated for each feature. Multivariate survival
analysis (Cox model) was used to assess the indepen-
dent prognostic value of the different features.
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3. Results
In the 273 FIGO stage 1–4 cases of endometrioid
endometrial adenocarcinoma studied, the median age
was 66 (range 32–94) years. With median follow-up of
61 months (range 1–209), 34 (12.5%) patients devel-
oped metastases.
Table 3 shows the correlation between MSI and the
other variables. MSI-H is associated with high grade
(grades 2 and 3), whereas grade 1 cancers more often
are MSS or MSI-L.
Table 4 summarizes the univariate prognostic value
of the features analysed for all FIGO stages. Age (68
vs. >68), FIGO stage and grade had a prognostic value
but MSI did not. For the FIGO stage 1 patients, grade
(as grade 1 vs. grades 2 + 3) was not significant, nei-
ther were FIGO 1A, 1B or 1C, nor myometrium inva-
Table 3
Associations between MSI and parameters analysed in endome-
trial endometrioid cancer. MSS and MSI-L were classified as MSI-
negative (MSI−), MSI-H as MSI-positive (MSI+)
Parameter No. (%) p-value1
MSI− MSI+
FIGO stage 1–4
Age <68 years 95 (85) 17 (15)
68 years 78 (79) 21 (21) 0.29
FIGO 1 144 (84) 27 (16)
2 16 (73) 6 (27)
3 8 (67) 4 (33)
4 5 (83) 1 (17) 0.28
Grade 1 84 (91) 8 (9)
2 63 (77) 19 (23)
3 26 (70) 11 (30) 0.006
FIGO stage 1
Age <68 years 81 (86) 13 (14)
68 years 63 (82) 14 (18) 0.29
FIGO stage 1
1a 22 (82) 5 (19)
1b 93 (86) 15 (14)
1c 29 (81) 7 (19) 0.67
Myometrium Invasion
inner half 115 (85) 20 (15)
outer half 29 (81) 7 (19) 0.50
Grade 1 74 (90) 8 (10)
2 55 (80) 14 (20)
3 15 (75) 5 (25) 0.10
Grade 1 74 (90) 8 (10)
2 + 3 70 (79) 19 (21) 0.03
Note: 1p – probability of no difference.
sion. MSS and MSI-L cancers (84% of all cases) had
a good prognosis, whereas MSI-H cancers (16%) were
associated with a worse survival, as shown by the sur-
vival curve (Fig. 2). The 5- and 10-year recurrence-
free survival rates were 98% and 95%, respectively,
in the MSS/MSI-L vs. 85% and 73%, respectively, in
the MSI-H cancer patients. In the multivariate analy-
sis, MSI had a prognostic value only in FIGO stage 1
cancers.
4. Discussion
In this population-based endometrioid endometrial
cancer study MSI showed a prognostic value but only
for FIGO stage 1 cancers. MSI is an objective marker
and many studies found MSI to be a valuable and
promising prognostic indicator in other types of cancer,
especially gastric and colonic cancer. For endometrial
cancer the results have been conflicting with as many
studies showing prognostic value as not. A large multi-
center study found that MSI-L/MSS vs. MSI-H was not
of prognostic value [44]. We could confirm this for all
FIGO stages analysed together. However, in the 2007
study no subgroup analysis on FIGO stage 1 cases was
performed.
Another recent study of interest analysed early stage
endometrioid cancers with the same panel of markers
as we did (these markers have been proven to be more
reliable than the ones used in other series [8,9,42]).
The study concluded on a negative prognostic value of
MSI-H cases, but in contrast to our study all of their
cases were radiation-treated [6]. MSI-L and MSI-H
were found in 11% and 16% of the cancers analyzed
(totalling 27%). Of 17 previous studies on MSI in en-
dometrial cancer, the prevalence of MSI widely var-
ied from 9% to 45% [1,4,5,7,10,12,16,17,19,25,26,28,
29,32,33,42,44] (Table 1). The table also illustrates the
enormous variation in the numbers of patients, stages,
histotypes and molecular techniques used in the differ-
ent studies. MSI is also found in atypical hyperplasia
[18], indicating that MSI is an early event in a sub-
set of endometrial cancer. Late stage endometrial can-
cers are more likely to have accumulated many genetic
changes, this is supported by our findings of an in-
creasing MSI-H rate in FIGO 2 cancers of 27% and in
FIGO 3 cancers 33%. For FIGO 4 there where lack-
ing data for 4 out of 10 cases, and only 1 case were
MSI-H (Table 3). It is understandable that the value
of MSI (an early stage prognostic marker) is limited
in late stage cancers. The use by other studies of both
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Table 4
Survival data stratified for the different parameters analyzed
Parameters Variable Events/At risk (%) p-value1 HR2 95% CI3
(log rank)
FIGO stage 1–4
Age 68 years 10/149 (6.7)
>68 years 24/124 (19.4) <0.0001 3.9 1.9–8.2
FIGO 1 14/224 (6.3)
2 7/27 (25.9) 6.1 2.4–15.2
3 3/12 (25.0) 4.1 1.2–14.6
4 10/10 (100.0) <0.0001 67.4 27.7–170.0
FIGO grade 1 6/120 (5.0)
2 15/105 (14.3)
3 13/48 (27.1) <0.0001 n.d.4 n.d.4
MSI MSS 15/148 (10.1)
MSI-L 3/25 (12.0) n.d.4 n.d.4
MSI-H 7/38 (18.4) 0.16 n.d.4 n.d.4
MSI MSS/MSI-L 18/173 (10.4)
MSI-H 7/38 (18.4) 0.06 n.d.4 n.d.4
FIGO stage 1
Age (years) 68 4/126 (3.2)
>68 10/98 (10.2) 0.004 4.7 1.5–15.3
FIGO1 1a 1/53 (1.9)
1b 10/129 (7.8) 5.2 0.7–40.5
1c 3/42 (7.1) 0.22 3.9 0.4–37.9
Myometrium invasion inner half 11/182 (6.0)
outer half 3/42 (7.1) 0.94 n.d.4 n.d.4
FIGO grade 1 4/108 (3.7)
2 8/87 (9.2)
3 2/29 (6.9) 0.25 n.d.4 n.d.4
FIGO grade 1 4/108 (3.7)
2 + 3 10/116 (8.6) 0.09 n.d.4 n.d.4
MSI5 MSS 6/125 (4.8)
MSI-L 0/19 (0) n.d.4 n.d.4
MSI-H 4/27 (14.8) 0.02 4.6 1.3–16.7
MSI5 MSS/MSI-L 6/144 (4.2)
MSI-H 4/27 (14.8) 0.005 5.2 1.5–18.8
Notes: 1p – probability of no difference; 2HR – hazard ratio; 3CI – confidence interval; 4n.d. – not done, not significant or divided by zero
error; 5MSI – microsatellite instability; MSS – microsatellite stable; MSI-L – microsatellite instability at low frequency; MSI-H – microsatellite
instability at high frequency.
types I and II cancers which follow different pathways
is likely to further blur the evaluation of the prognostic
value of MSI. We conclude therefore that one must be
careful when attempting to draw any conclusions from
these studies for the most frequent endometrial cancer:
FIGO stage 1 endometrioid endometrial cancer.
Interestingly, the behaviour of endometrioid en-
dometrial cancer according to MSI seems the opposite
of that in colonic and gastric cancers, where MSI-H tu-
mors have a better prognosis [34,36]. Chemotherapy is
widely used in these cancers, contrasting the habits in
early stage endometrioid cancer. This raised the ques-
tion whether MSI-H cancers may be especially sensi-
tive for chemotherapy. If so, FIGO stage 1 endometri-
oid cancer patients with MSI-H may benefit from ad-
juvant chemotherapy. Chemotherapy data is unfortu-
nately incomplete for our patient population.
The sharp increase of endometrial cancer incidence
during the last few decades in the western world and
increasingly in many young patients of childbearing
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Fig. 2. Survival curve of the FIGO 1 endometrioid endometrial cancer according to MSI-status. (Colors are visible in the online version of the
article; http://dx.doi.org/10.3233/ACP-CLO-2010-0550.)
age, raises the important point of fertility-sparing and
ovary-saving surgery. Patients with obesity, diabetes
or cardiovascular disease amongst others, also would
benefit from less aggressive surgery such as vaginal
hysterectomy and no lymphadenectomy. This of course
requires reliable preoperative identification of low-and
high risk patients. MSS/MSI-L status is shown here
to be an adequate marker to identify endometrioid
FIGO stage 1 cancers with a very low risk, while
MSI-H identifies the small subgroup of aggressive can-
cers. This may be used to indicate radical surgery, ra-
diotherapy and early start of postoperative adjuvant
chemotherapy as suggested above.
The molecular causes and consequences of MSI in
sporadic endometrial carcinomas have been less well
studied. In sporadic colorectal cancers, MSI is asso-
ciated with somatic hypermethylation of the promoter
of the mismatch repair gene hMLH1 [11,35] as is the
case in the great majority of sporadic endometrial car-
cinomas [14,21]. Furthermore, RASSF1A promoter is
also frequently methylated in endometrial carcinoma
and significantly associated with MSI [20,30]. APC
promoter hypermethylation is correlated with MSI in
endometrioid endometrial carcinomas [27]. Moreover,
high frequency promoter methylation of P16, MGMT
[13], and RARb2 [2], were found in endometrial carci-
noma and lack of CDH13 promoter hypermethylation
was prognostic [39].
Since promoter hypermethylation of certain genes
appears to be an early and frequent event in endome-
trial carcinogenesis, this raises the question of what
are the molecular interactions between a tendency for
promoter hypermethylation and other genetic changes
in FIGO stage 1 endometrial endometrioid adenocar-
cinoma cases. Type I cancers often show K-ras muta-
tions which are correlated with MSI [24]. We recently
found that decreased P21 and survivin overexpression
were prognostic [38]. Therefore, what is the prognostic
value of combinations of promoter methylation, MSI
and genetic changes in FIGO stage 1 endometrial en-
dometrioid adenocarcinoma cases?
Our population-based endometrioid FIGO stage 1
endometrial cancer study on MSI is one of the largest
with long and complete long follow up. We conclude
that in FIGO stage 1 endometrial endometrioid adeno-
carcinoma cases, MSI assessed with highly sensitive
pentaplex polymerase chain reaction has independent
prognostic value.
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